ALGN vs SOLV vs NVST Stock Comparison

Align Technology, Solventum and Envista Holdings Prices as of Oct 28, 2026 Peers: Industry group
1 more company in this comparison (DROR) Create a free account to keep reading and compare up to 10 companies.
SOLV Solventum Corp
$81.83 -8.6% 1M +15.4% 1Y
Market cap
$13.92B
P/E
9.9x
Revenue (TTM)
$8.31B
Div. yield
–
Medical Devices Healthcare
6 wins

Head to Head

11 decided of 12

Solventum leads on 6 of the 12 questions below (Solventum 6, Envista Holdings 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionALGNSOLVNVSTLeader
Larger companyMarket capitalisation $10.94B $13.92B $3.84B SOLV
Cheaper on earningsLower P/E, profitable companies only 26.6x 9.9x 40.8x SOLV
Cheaper on forward earningsLower price / next fiscal year consensus EPS 14.0x 12.0x 16.0x SOLV
Faster revenue growthRevenue growth, trailing twelve months +4.4% -0.9% +11.9% NVST
More profitableNet margin, trailing twelve months 10.0% 17.3% 3.3% SOLV
Better return on capitalReturn on invested capital — 17.6% 2.5% SOLV
Less leveragedLower net debt / EBITDA — 1.8x 0.8x NVST
Higher dividend yieldTrailing dividend yield — — — –
Better 1-year returnPrice return, last 12 months +15.4% +15.4% +19.3% NVST
Better 5-year returnAnnualised price return, 5 years -24.5%/yr — -9.4%/yr NVST
Less volatileAnnualised volatility, 1 year 39.1% 30.0% 37.8% SOLV
Higher overall scoreMean of the five percentile scores vs peers 66/100 66/100 74/100 NVST

Percentile Scorecard

ALGNSOLVNVST

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisALGNSOLVNVST
Valuation 89 #27 of 227 80 #47 of 227 97 #7 of 227
Growth 23 #169 of 219 56 #97 of 219 51 #108 of 219
Profitability 89 #23 of 205 85 #32 of 205 75 #53 of 205
Financial Health 42 #139 of 237 20 #190 of 237 52 #115 of 237
Shareholder Returns 89 #16 of 135 90 #14 of 135 96 #6 of 135
Overall 66 66 74
  • ALGN ranked among 247 companies in Medical Devices and Diagnostics
  • SOLV ranked among 247 companies in Medical Devices and Diagnostics
  • NVST ranked among 247 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodALGNSOLVNVSTSPY
1 month +5.9%-8.6%+0.9% +0.9%
3 months -14.7%-7.6%-15.6% +5.9%
6 months -13.9%+23.1%-7.6% +8.5%
Year to date -1.6%+3.3%+10.3% +13.3%
1 year +15.4%+15.4%+19.3% +12.4%
3 years -19.5%—+1.8% +88.1%
3 years, per year -7.0%—+0.6% +23.5%
5 years -75.4%—-38.8% +68.2%
5 years, per year -24.5%—-9.4% +11.0%
10 years +80.4%—— +263.4%
10 years, per year +6.1%—— +13.8%

Risk

MeasureALGNSOLVNVSTSPY
Volatility, 1Y 39.1%30.0%37.8% 12.7%
Downside volatility, 1Y 37.0%28.8%34.6% 12.7%
Beta vs S&P 500, 1Y 1.300.571.15 1.00
Return / volatility, 1Y 0.390.510.51 0.98
Max drawdown, 5Y -82.4%-40.0%-71.0% -25.4%
From 52-week high -22.2%-11.5%-20.9% -0.9%
52-week high $197.51$92.45$30.26 $779.14
52-week low $131.91$62.49$18.95 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleALGNSOLVNVST
P/E now vs peer median 26.6xmedian 28.8x 9.9xmedian 28.8x 40.8xmedian 28.8x
P/S now vs peer median 2.6xmedian 3.0x 1.7xmedian 3.0x 1.3xmedian 3.0x
EV/EBITDA now vs peer median 12.3xmedian 17.4x 7.2xmedian 17.4x 10.7xmedian 17.4x
P/FCF now vs peer median 17.3xmedian 25.7x -118.0xmedian 25.7x 15.5xmedian 25.7x
P/B now vs peer median 2.6xmedian 2.4x 2.9xmedian 2.4x 1.2xmedian 2.4x
PEG now vs peer median 2.18median 1.03 —median 1.03 -1.84median 1.03

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsALGNSOLVNVST
Revenue $4.14B $8.31B $2.86B
Gross profit $2.82B $4.55B $1.58B
Operating income $547.59M $2.08B $273.60M
Net income $413.58M $1.43B $95.00M
Free cash flow $633.57M -$118.00M $248.10M
R&D $377.00M $725.00M $120.80M
EPS (diluted) $5.78 $8.27 $0.58
Cash & equivalents $1.10B $403.00M $1.13B
Total debt – $5.08B $1.44B
Shares (diluted) 71.52M 173.30M 164.10M
Enterprise value $6.68B $10.44B -$709.24M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricALGNSOLVNVST
P/E 26.6x 9.9x 40.8x
P/FCF 17.3x -118.0x 15.5x
P/Operating cash flow 14.5x 66.6x 12.7x
P/S 2.6x 1.7x 1.3x
P/B 2.6x 2.9x 1.2x
P/Tangible book 2.6x 5.8x 1.6x
EV/EBITDA 12.3x 7.2x 10.7x
EV/EBIT 18.0x 9.0x 15.2x
EV/Revenue 2.4x 2.2x 1.5x
EV/FCF 15.5x -157.6x 16.7x
EV/Operating cash flow 13.0x 89.0x 13.7x
PEG (3Y EPS CAGR) 2.18 – -1.84

Growth

14 metrics
MetricALGNSOLVNVST
Revenue growth (1Y) 4.4% -0.9% 11.9%
Revenue CAGR (3Y) 3.5% – 3.4%
Gross profit growth (1Y) 1.8% -0.6% 13.1%
Gross profit CAGR (3Y) 2.6% – 2.3%
Operating income growth (1Y) -8.8% 167.2% 79.6%
Operating income CAGR (3Y) -0.8% – -4.4%
Net income growth (1Y) -5.5% 277.4% 76.6%
Net income CAGR (3Y) 9.6% – -24.0%
EPS growth (1Y) -4.1% 281.5% 82.8%
EPS CAGR (3Y) 12.2% – -22.2%
Operating cash flow growth (1Y) 3.4% -64.3% 3.6%
Operating cash flow CAGR (3Y) -4.3% – 8.8%
Free cash flow growth (1Y) 0.3% -180.3% -3.8%
Free cash flow CAGR (3Y) 1.2% – 15.8%

Profitability

14 metrics
MetricALGNSOLVNVST
Gross margin 68.0% 54.7% 55.2%
EBITDA margin 19.4% 31.1% 13.6%
Operating margin 13.2% 25.0% 9.6%
Pretax margin 13.7% 20.4% 8.2%
Net margin 10.0% 17.3% 3.3%
FCF margin 15.3% -1.4% 8.7%
Operating cash flow margin 18.3% 2.5% 10.6%
Return on equity 9.9% 29.4% 3.1%
Return on assets 6.5% 10.1% 1.7%
Return on invested capital – 17.6% 2.5%
Return on capital employed 12.3% 19.8% 5.7%
Asset turnover 0.7x 0.6x 0.5x
Cash conversion (OCF / net income) 1.8x 0.1x 3.2x
Stock comp / revenue 4.3% 2.0% 1.4%

Financial Health

11 metrics
MetricALGNSOLVNVST
Debt / assets – 35.7% 25.7%
Debt / equity – 1.1x 0.5x
Net debt / EBITDA – 1.8x 0.8x
Debt / FCF – -43.0x 5.8x
Liabilities / assets 34.0% 66.3% 45.0%
Equity / assets 66.0% 33.7% 55.0%
Interest coverage – – –
Current ratio 1.4x 1.0x 2.4x
Quick ratio 1.2x 0.5x 1.9x
Cash ratio 0.6x 0.1x 1.4x
Altman Z-score 4.64 2.14 1.75

Shareholder Returns

7 metrics
MetricALGNSOLVNVST
Dividend yield – – –
Net buyback yield 2.3% 2.6% 4.3%
Shareholder yield 2.3% 2.6% 4.3%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusALGNSOLVNVST
Forward P/E 14.0xFY2026 12.0xFY2026 16.0xFY2026
EPS, next fiscal year $10.95FY2026 $6.83FY2026 $1.50FY2026
EPS growth, next FY +4.2%FY2026 +11.8%FY2026 +26.1%FY2026
EPS growth, the year after +16.3% +12.7% +16.7%
Revenue, next fiscal year $3.86BFY2026 $7.70BFY2026 $2.99BFY2026
Revenue growth, next FY -4.2%FY2026 -7.4%FY2026 +9.8%FY2026
Revenue growth, the year after +3.5% +5.4% +2.6%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersALGNSOLVNVST
Held by institutions 100.0% 73.9% 100.0%
Institutions holding 675 878 382
Change in shares held, QoQ +4.2% -0.8% +6.4%
Institutions buying 292 369 200
Institutions selling 268 284 129
Buyers to sellers 1.09 1.30 1.55

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ALGNSOLVNVST
ALGN 1.00 0.47 0.69
SOLV 0.47 1.00 0.44
NVST 0.69 0.44 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ALGN, SOLV and NVST?

Solventum (SOLV) is the largest by market capitalisation: Align Technology (ALGN) $10.94B, Solventum (SOLV) $13.92B, Envista Holdings (NVST) $3.84B.

Which stock is cheaper, ALGN, SOLV and NVST?

Solventum (SOLV) trades on the lowest price-to-earnings ratio (Align Technology (ALGN) 26.6x, Solventum (SOLV) 9.9x, Envista Holdings (NVST) 40.8x). On next year's consensus earnings, Solventum (SOLV) is cheapest (Align Technology (ALGN) 14.0x, Solventum (SOLV) 12.0x, Envista Holdings (NVST) 16.0x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Envista Holdings (NVST) grew revenue fastest over the trailing twelve months: Align Technology (ALGN) +4.4%, Solventum (SOLV) -0.9%, Envista Holdings (NVST) +11.9%.

Which company is more profitable?

Solventum (SOLV) has the highest net margin (Align Technology (ALGN) 10.0%, Solventum (SOLV) 17.3%, Envista Holdings (NVST) 3.3%). On return on invested capital, Solventum (SOLV) leads (Solventum (SOLV) 17.6%, Envista Holdings (NVST) 2.5%).

Which stock has performed better?

Over the past year Envista Holdings (NVST) returned the most: Align Technology (ALGN) +15.4%, Solventum (SOLV) +15.4%, Envista Holdings (NVST) +19.3%. Over five years, Envista Holdings (NVST) compounded fastest (Align Technology (ALGN) -24.5%/yr, Envista Holdings (NVST) -9.4%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Solventum (SOLV) has been the steadiest (Align Technology (ALGN) 39.1%, Solventum (SOLV) 30.0%, Envista Holdings (NVST) 37.8%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ALGN, SOLV and NVST?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Solventum (SOLV) leads on 6. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.